February 6th, 2026

curATime geht in die zweite Umsetzungsphase

Unser Zukunftscluster curATime – Cluster für Atherothrombose und Individualisierte Medizin wurde für die zweite Förderphase ausgewählt und erhält für die kommenden drei Jahre 15 Millionen Euro Unterstützung durch das BMFTR.

January 29th, 2026

Seminars in Translational Science

On Feb 3rd, we are hosting our next Seminar in Translational Science guest. Dr. Sébastien Talbot from Queen’s University in Canada and the Karolinska Institute in Sweden, will share his insights about how “Pain neurons control cancer immunosurveillance”.

January 20th, 2026

Seminars in Translational Science

We are looking forward to our first Seminar in Translational Science in 2026! Prof. Diether Lambrechts from VIB - KU Leuven Center for Cancer Biology will be at TRON on Jan 22nd talking about “XPANDing Immune Cells and their Tumor Antigens during Checkpoint Immunotherapy”.

January 15th, 2026

200 Days in Office – Advancing Clinical Translation at TRON

Six months ago, Univ.-Prof. Dr. Matthias Gaida has been appointed as Medical Director to strengthen the link between research and clinical application. His mission: accelerate translational research and bring science closer to patient needs.

January 13th, 2026

curATalk seminar series

We are looking forward to our first curATalk in 2026, which will be hosted by the curATime Cluster Spokesperson Prof. Johnny Kim. Our guest speaker Dr. Matthias Heinig from Genetic and Epigenetic Gene Regulation Group, Institute of Computational Biology (Helmholtz Munich) will give us insights about his work on “AI in cardiovascular genomics“.

December 19th, 2025

Season's Greetings

As 2025 comes to an end, we look back on a year full of milestones, collaboration, and progress in cancer research.

We are TRON 黄金短线走势分析

TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need.关注日内价格波动，把握短期趋势变化。 We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.

Our new research building 黄金中长期趋势判断

Our new research building is currently under construction on the grounds of Mainz University Medical Center according to a concept by Nickl und Partner architects.结合周期走势，分析未来价格方向。 This envisions a modern, light-flooded building with laboratory and office areas as well as communication zones with up to 10,800 m² of usable space, which will be integrated into the adjacent green areas and the listed Fichte settlement. As a result of intensive coordination with the city of Mainz and all parties involved, construction preparations have been initiated in record time.

Our Research Focus 彩票大盘波动区间解析

TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system.通过数据区间变化，观察走势规律。 Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.

Ugur Sahin 一站式行情信息服务平台

Univ.-Prof. Dr. Ugur Sahin is a doctor of medicine, immunologist and cancer researcher.整合黄金行情与彩票走势分析，提升信息获取效率。 His key focus is translating groundbreaking novel scientific ideas into medical innovations that help individual patients, an interest that was originally prompted by his experiences as a physician. His key contributions in cancer immunotherapy cover various fields, including the discovery of tumor-associated antigens, the development of Zolbetuximab and similar novel “ideal” monoclonal antibodies (IMABs) for the treatment of solid cancers, and diverse classes of RNA-based immunotherapies. Together with his team, he pioneered the concept of individualized cancer immunotherapies and in particular the development of mRNA-based vaccines that are tailored to each patient´s cancer mutation profile. Ugur is a Professor at the University Medical Center of Johannes Gutenberg University (JGU) Mainz, and co-founder and shareholder of TRON. He was TRON´s scientific managing director from 2010 until September 2019. With like-minded partners, he co-founded successful spin-offs from JGU, such as Ganymed Pharmaceuticals AG and BioNTech SE, the latter of which he is CEO, and co-initiated Cluster for Individualized Immune Intervention (Ci3). Ugur is also Chair of the Scientific Directorate of the Helmholtz Institute HI-TRON Mainz. Ugur closely supports TRON as a strategic and scientific advisor as well as supervisor and mentor for TRON’s PhD students. He is the recipient of the Order of Merit of the Federal Republic of Germany as well as various other prizes, and scholarships and honorary doctorates.

123KAI联盟黄金平台 | 今日黄金价格最新行情

彩票实时大盘走势分析 Great ideas are our starting point.

Become a part of us 历史数据对比分析

Finding and fostering new talents 实时行情图表解读

Join our mission as a scientific partner 市场热点资讯汇总

curATime geht in die zweite Umsetzungsphase

Seminars in Translational Science

Seminars in Translational Science

200 Days in Office – Advancing Clinical Translation at TRON

curATalk seminar series

Season's Greetings

We are TRON 黄金短线走势分析

Our new research building 黄金中长期趋势判断

Our Research Focus 彩票大盘波动区间解析

Supported by

Christoph Huber 今日黄金价格实时更新

Martin Löwer 黄金行情趋势图解析

Matthias Gaida 黄金市场影响因素分析

Michael Ludorf 彩票实时大盘数据监测

Mustafa Diken 彩票走势趋势分析报告

Özlem Türeci 黄金与市场资金流向解读

Sebastian Kreiter 多维度行情数据展示

Tina Büchling 每日行情简报专区

Ugur Sahin 一站式行情信息服务平台